Aesica Appoints New Product Release Manager
Aesica has appointed Adam Burgess to the position of Product Release Manager. Adam’s wide ranging role includes managing the Qualified Persons team; directing and controlling QP activities in line with operational requirements, the role also involves the development of quality systems, product release, facilitating process improvements and acting as a Qualified Person.
Based at Queenborough, UK Adam has responsibility for pharmaceutical quality assurance across the Kent-based site. A key function is to ensure on time release of products. He will work closely with production personnel at the site, with the specific goal of ensuring that operational departments build quality into their processes and organisational structures. Adam reports directly to Christine Ernst, the Site Head of Quality at Aesica, Queenborough, UK.
Previously, he held the position of Manager, Defective Medicines Report Centre and Import Notification at the MHRA and was an active Qualified Person at Martindale Pharma. Prior to that, he worked as a QA Manager in Preclinical Quality Assurance at GlaxoSmithKline. His expertise reaches across both commercial and clinical trial products including steriles, non-sterile tablets, capsules and liquids. Adam brings QA experience in laboratory, packaging and manufacturing area settings. He has strong skills in the risk assessment of pharmaceutical products and has authored position papers focused both on product quality and patient safety implications of unplanned events.
Remarking on his new position, Adam Burges said: “I am delighted to be appointed to this role at Aesica. It affords me the opportunity to return to pharmaceutical manufacturing and packaging, bringing the experience that I have gained at the UK regulator. This experience will help me to further enhance and drive quality culture initiatives across the company — in particular at Queenborough. I am looking forward to leading the product release team to ensure that all staff fully understand customer needs, consistently deliver results, whilst maintaining the high quality levels demanded and expected.”
Commenting on Adam Burgess’s appointment, Indira Walker, Corporate Quality Director at Aesica remarked: “We are delighted that Adam has joined our QA team. He brings strong QA expertise and we are especially impressed by his combined experience of working both for prominent pharmaceutical companies and the MHRA regulatory authority.”
She continued: “We look forward to Adam contributing significantly to making further inroads into driving up QA standards so that we deliver the most consistent and best-in-class quality of service within the industry.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance